PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer
Publication Date
2024
Content Type
Article
PubMed ID:
Citation
Journal of Clinical Oncology (2024) 42(17):2050-2060